(Q39947947)

15 September 2017

1 reference

title

Individualization of Dosage of Antiarrhythmic Drugs (English)

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)32097-1

12 February 2023

author name string

K. M. Kessler

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4609363

12 February 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=4609363

12 February 2023

publication date

1 September 1974

1 reference

full work available at URL

15 September 2017

https://api.elsevier.com/content/article/PII:S0025712516320971?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)32097-1

https://api.elsevier.com/content/article/PII:S0025712516320971?httpAccept=text/plain

12 February 2023

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)32097-1

Medical Clinics of North America

12 February 2023

published in

1 reference

15 September 2017

volume

58

1 reference

15 September 2017

issue

5

1 reference

15 September 2017

page(s)

1019-1026

1 reference

The rate of decline of diphenylhydantoin in human plasma

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Inhibition of diphenylhydantoin metabolism by chloramphenicol

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Hypotension due to 5 per cent plasma protein fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Pharmacokinetics of lidocaine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Serum quinidine concentration in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Inhibition of drug metabolism by chloramphenicol

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Plasma levels of lidocaine after intramuscular administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

SOME CELLULAR AND METABOLIC CONSIDERATIONS RELATING TO THE ACTION OF QUINIDINE AS A PROTOTYPE ANTIARRHYTHMIC AGENT

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Metabolism of procainamide in rhesus monkey and man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Intramuscularly and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Quinidine Excretion in Aciduria and Alkaluria

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Effect of Lidocaine on Ventricular Arrhythmias in Patients with Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Comparison of two methods for quinidine determination and chromatographic analysis of the difference

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Intoxication with 5,5-diphenylhydantoin (Dilantin): clinical features, blood levels, urinary metabolites, and metabolic changes in a child

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Acute diphenylhydantoin intoxication following halothane anesthesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Quinidine Elimination in Patients with Congestive Heart Failure or Poor Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Pharmacokinetic of procainamide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Drug therapy. Serum drug concentrations as therapeutic guides

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Biochemical and genetic factors regulating dilantin metabolism in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Some Causes of Ineffectiveness of Diphenylhydantoin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Pharmacogenetics: defective enzymes in relation to reactions to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Diphenylhydantoin Metabolism in Uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Abnormal pharmacokinetics of phenytoin in a patient with uraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Influence of disease on binding of drugs to plasma proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Disposition kinetics of lidocaine in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Plasma diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

The effect of phenyramidol on the metabolism of diphenylhydantoin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Interrelationships of Hepatic Blood Flow, Cardiac Output, and Blood Levels of Lidocaine in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Identification of glycinexylidide in patients treated with intravenous lidocaine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Studies of quinidine plasma levels and rate of decline following cessation of quinidine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Pharmacodynamics of Propranolol in Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Interaction between phenytoin and the benzodiazepines

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Pharmacokinetics of Procainamide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2932097-1

7 January 2021

Copper deficiency in a premature infant fed on iron-fortified formula

series ordinal

6

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)32097-1

Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution

12 February 2023

series ordinal

46

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(16)32097-1

12 February 2023

Identifiers

0 references

1 reference